http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2350648-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_715946dfd122eb9277028d69e0cf56a3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2006-05-30^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-01-25^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfe41121edd0ec95d39ec520a410beb8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_954fb90fa8ca69572cd2d5115f3cc078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_906c804db7d3ba2ae2ae3e8864b516e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_792a27fd9b6746175aadb36061f37d63 |
| publicationDate | 2011-01-25^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2350648-T3 |
| titleOfInvention | COMPOSITIONS AND METHODS TO PREACH THE RESULT OF A TREATMENT. |
| abstract | A method for predicting the result of treating a patient with 5-FU, which comprises a) incubating an isolated sample of said patient with a composition comprising (i) at least three in situ hybridization probes that are fixed to at least three 5-FU path markers in relation to association with the main resistance of cancer cells to the treatment of 5-FU, where the hybridization probes are nucleic acid probes or nucleic acid analog probes, and where the markers are selected from the group consisting of thymidine synthase (hereinafter TYMS), dihydrofolate reductase (hereinafter DHFR), Thymidine phosphorylase (hereinafter TP), dihydropyrimidine dehydrogenase (hereinafter DPD), methylenetetrahydrofolate reductase (hereinafter MTHFR), thymidine kinase (in TK) and methionine synthase (hereinafter MTR); (ii) at least one probe that is fixed to at least one reference marker in situ; and optionally (iii) at least one blocking probe; (b) determine the level of gene abnormality of the at least three markers of (a) in said sample by an analysis, wherein said analysis is based on the correlation of a signal from said markers of the 5-FU path and a signal of said at least one reference marker; and (c) predict the outcome of 5-FU treatment in said patient based on the level of gene abnormality determined, where said patient is a cancer patient who has not been treated with 5-FU. |
| priorityDate | 2005-05-31^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 1000 of 1713.
| Next Page | Last Page |